Niti Goel

Adjunct Assistant Professor in the Department of Medicine

Medicine, Rheumatology and Immunology

ORCID iD

https://orcid.org/0000-0001-5869-5157

More About This Person

At a Glance

Credentials
1. Education

Academic Experience
1. Current Duke Appointments & Affiliations

Global Scholarship

Keywords

Research

Scholarly Works

Teaching & Mentoring

Recognition

Professional Activities

Embed Profile Data

Embed Profile Data

Scholarly Works - Conferences

Characteristics of Patients with Psoriatic Arthritis Presenting with Axial Involvement: Results of a Prospective International Multicenter Study (AXIS)

Conference ARTHRITIS & RHEUMATOLOGY · September 2024 Link to item Cite

Clinical and Imaging Characteristics of Individuals Who Underwent Knee Replacement During Years 3 to 5 in the FORWARD Study: A Post Hoc Analysis

Conference ARTHRITIS & RHEUMATOLOGY · October 2023 Link to item Cite

Effects of Sprifermin on a Novel Outcome of Osteoarthritis Symptom Progression: Post Hoc Analysis of the FORWARD Study

Conference ARTHRITIS & RHEUMATOLOGY · October 2023 Link to item Cite

Impact of Sprifermin on Denuded Areas of Subchondral Bone (dABs): A Post Hoc Analysis of the FORWARD Study

Conference ARTHRITIS & RHEUMATOLOGY · October 2023 Link to item Cite

POS0882 SCREENING/REFERRAL STRATEGIES FOR THE EARLY RECOGNITION OF PSA AMONG PATIENTS WITH PSORIASIS: RESULTS OF A GRAPPA SURVEY

Conference Annals of the Rheumatic Diseases · June 2023 Full text Cite

AB1682 ARE CHANGES IN SELF-REPORTED NSAID DOSE ASSOCIATED WITH MEANINGFUL CHANGES IN PAIN OR OTHER HEALTH OUTCOMES IN RHEUMATIC DISEASES?

Conference Annals of the Rheumatic Diseases · June 2023 Full text Cite

POS1348 EFFECTS OF SPRIFERMIN ON A NOVEL OUTCOME OF OSTEOARTHRITIS SYMPTOM PROGRESSION: POST-HOC ANALYSIS OF THE FORWARD RANDOMIZED TRIAL

Conference Annals of the Rheumatic Diseases · June 2023 Full text Cite

Lack of Racial and Ethnic Diversity in Clinical Trials of Psoriatic Arthritis

Conference ARTHRITIS & RHEUMATOLOGY · September 2022 Link to item Cite

POS1342 DEPLETION OF KLRG1+ T CELLS IN A FIRST-IN-HUMAN CLINICAL TRIAL OF ABC008 IN INCLUSION BODY MYOSITIS (IBM)

Conference Annals of the Rheumatic Diseases · June 2022 Full text Cite

AB0953 Lack of Racial Diversity in Clinical Trials of Psoriatic Arthritis

Conference Annals of the Rheumatic Diseases · June 2022 Full text Cite

Depletion of Large Granular Lymphocytes in A First-in-Human Clinical Trial of ABC008

Conference AMERICAN JOURNAL OF HEMATOLOGY · October 2021 Link to item Cite

Depletion of KLRG1+T Cells in a First-in-human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM)

Conference ARTHRITIS & RHEUMATOLOGY · September 2021 Link to item Cite

CD8 Positron Emission Tomography (PET/CT) Imaging with 89Zr-Df-IAB22M2C in Patients with Inclusion Body Myositis

Conference ARTHRITIS & RHEUMATOLOGY · September 2021 Link to item Cite

OP0229 THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) TREATMENT RECOMMENDATIONS 2021

Conference Annals of the Rheumatic Diseases · June 2021 Full text Cite

AB0737 MEASUREMENT PROPERTIES OF RADIOGRAPHIC OUTCOME MEASURES IN PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW FROM THE GRAPPA-OMERACT INITIATIVE

Conference Annals of the Rheumatic Diseases · June 2020 Full text Cite

AB0794 CLINICAL TRIAL DISCRIMINATION OF PHYSICAL FUNCTION INSTRUMENTS FOR PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW

Conference Annals of the Rheumatic Diseases · June 2020 Full text Cite

Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated with the Selective Immunoproteasome Inhibitor, KZR-616

Conference ARTHRITIS & RHEUMATOLOGY · October 1, 2019 Link to item Cite

Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome

Conference ARTHRITIS & RHEUMATOLOGY · October 1, 2019 Link to item Cite

Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial

Conference ARTHRITIS & RHEUMATOLOGY · October 1, 2019 Link to item Cite

FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL

Conference Annals of the Rheumatic Diseases · June 2019 Full text Cite

SAT0395 RESPONSIVENESS AND CLINICAL TRIAL DISCRIMINATION OF SWOLLEN AND TENDER JOINT COUNTS FOR THE MEASUREMENT OF MSK DISEASE ACTIVITY IN PSORIATIC ARTHRITIS

Conference Annals of the Rheumatic Diseases · June 2019 Full text Cite

The 66/68 Joint Count for the Measurement of MSK Disease Activity/Peripheral Joint Activity in Psa: A Grappa-Omeract Working Group Initiative

Conference ARTHRITIS & RHEUMATOLOGY · September 1, 2018 Link to item Cite

Psoriatic Arthritis Impact of Disease (PsAID12) Was Provisionally Endorsed at Omeract 2018 As Core Instrument to Measure Psoriatic Arthritis-Specific Health-Related Quality of Life in Randomized Controlled Trials and Longitudinal Observational Studies

Conference ARTHRITIS & RHEUMATOLOGY · September 1, 2018 Link to item Cite

Construct Validity of the Swollen and Tender Joint Counts for the Measurement of MSK Disease Activity in Psoriatic Arthritis

Conference ARTHRITIS & RHEUMATOLOGY · September 1, 2018 Link to item Cite

SAT0241 Patients' perspective on the efficacy and risks of glucocorticoids in ra – an initiative under the gloria project

Conference Annals of the Rheumatic Diseases · June 2018 Full text Cite

Quantiferon Testing in a Clinical Trial of Systemic Lupus Erythematosus

Conference ARTHRITIS & RHEUMATOLOGY · October 1, 2017 Link to item Cite

THU0677 Outcome measurement instruments for safety in rheumatology: a scoping review of available instruments to inform the omeract safety working group

Conference Annals of the Rheumatic Diseases · June 2017 Full text Cite

Feasibility and added value of meaningful patient involvement in the development of a core outcome set for psoriatic arthritis

Conference QUALITY OF LIFE RESEARCH · October 1, 2016 Link to item Cite

International Patient and Physician Consensus on Psoriatic Arthritis Outcomes for Clinical Trials

Conference ARTHRITIS & RHEUMATOLOGY · October 2016 Link to item Cite

Environmental Scan of Rheumatoid Arthritis Patient Registries Around the World: An Omeract Initiative

Conference ARTHRITIS & RHEUMATOLOGY · October 1, 2016 Link to item Cite

Randomized Clinical Trials of Systemic Lupus Erythematosus: Evaluating Differences in the Enrolled Populations

Conference ARTHRITIS & RHEUMATOLOGY · October 1, 2016 Link to item Cite

Assessment of Comparative Immunogenicity in Biosimilar Development: Immunogenicity and Pharmacokinetics Following a Single Dose of M923, a Proposed Biosimilar for Reference Adalimumab (HUMIRA (R)), Compared with US- and EU-Sourced Reference Adalimumab in Healthy Subjects

Conference ARTHRITIS & RHEUMATOLOGY · October 1, 2016 Link to item Cite

FRI0182 A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (A Proposed Biosimilar To Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects

Conference Annals of the Rheumatic Diseases · June 2016 Full text Cite

AB1035 Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Registries: A Qualitative Analysis of Data in clinicaltrials.gov

Conference Annals of the Rheumatic Diseases · June 2016 Full text Cite

FRI0346 Evaluating Differences in The Enrolled Populations of Randomized Clinical Trials of Systemic Lupus Erythematosus

Conference Annals of the Rheumatic Diseases · June 2016 Full text Cite

Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials

Conference Trials · December 2015 Full text Cite

FRI0047 The Patient Perspective on Absence of Disease Activity in Rheumatoid Arthritis: A Survey to Identify Key Domains of Patient Perceived Remission

Conference Annals of the Rheumatic Diseases · June 2015 Full text Cite

FRI0362 Rapid Acquisition of Data on the Patient Perspective in Rheumatoid Arthrtis Through a Digital Portal

Conference Annals of the Rheumatic Diseases · June 2015 Full text Cite

FRI0440 Lupus Clinical Trials: A Systematic Review of the Landscape and Opportunities for Improvement

Conference Annals of the Rheumatic Diseases · June 2014 Full text Cite

Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group.

Conference J Rheumatol · August 2011 Rheumatoid arthritis (RA) patients and healthcare professionals (HCP) recognize that episodic worsening disease activity, often described as a "flare," is a common feature of RA that can contribute to impaired function and disability. However, there is no ... Full text Link to item Cite

The Efficacy of Certolizumab Pegol Added to Methotrexate is Sustained Over 2 Years in the Treatment of Rheumatoid Arthritis

Conference JOURNAL OF RHEUMATOLOGY · June 1, 2010 Link to item Cite

Open-Label Certolizumab Pegol Is Effective In Patients Who Withdrew From Double-Blind Treatment Due To Non-Response

Conference JOURNAL OF RHEUMATOLOGY · June 1, 2010 Link to item Cite

Safety Update on Certolizumab Pegol (CZP) in Patients with Active Rheumatoid Arthritis (RA)

Conference JOURNAL OF RHEUMATOLOGY · June 1, 2010 Link to item Cite

THE EFFICACY OF CERTOLIZUMAB PEGOL ADDED TO METHOTREXATE IS SUSTAINED OVER 2 YEARS IN THE TREATMENT OF RHEUMATOID ARTHRITIS

Conference RHEUMATOLOGY · April 1, 2010 Link to item Cite

SAFETY UPDATE ON CERTOLIZUMAB PEGOL (CZP) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)

Conference RHEUMATOLOGY · April 1, 2010 Link to item Cite

Certolizumab Pegol Inhibits Radiographic Progression at 16 Weeks of Treatment. Results from Two RCTs (RAPID 1 And 2)

Conference JOURNAL OF RHEUMATOLOGY · November 1, 2009 Link to item Cite

Inhibition of Progression of Structural Damage by Week 16 with Certolizumab Pegol: Results from the RAPID Trials

Conference JOURNAL OF RHEUMATOLOGY · November 2009 Link to item Cite

Inhibition of progression of structural damage by week 16 with certolizumab pegol: Results from the RAPID trials

Conference ARTHRITIS AND RHEUMATISM · September 1, 2008 Link to item Cite

Early pulmonary involvement in systemic sclerosis: Associations with genetic, serologic, sociodemographic and behavioral factors in the GENISOS cohort.

Conference ARTHRITIS AND RHEUMATISM · September 1, 2005 Link to item Cite

Hip fracture trends from 1990-2001: Indirect evidence of improved diagnosis and treatment

Conference JOURNAL OF BONE AND MINERAL RESEARCH · October 1, 2004 Link to item Cite

Diagnosis and treatment of postmenopausal osteoporosis: Factors influencing house staff decision-making in primary care clinics.

Conference ARTHRITIS AND RHEUMATISM · September 1, 2003 Link to item Cite

Diagnosis and treatment of postmenopausal osteoporosis: Factors influencing house staff decision-making in primary care clinics.

Conference ARTHRITIS AND RHEUMATISM · September 2003 Link to item Cite

Patterns of anti-osteoporotic drug use among older community dwelling west Texans and associated factors.

Conference PHARMACOTHERAPY · October 1, 2002 Link to item Cite

Primary care resident evaluations for chronic health conditions: A failure to assess for osteoporosis

Conference JOURNAL OF BONE AND MINERAL RESEARCH · September 1, 2002 Link to item Cite

The budget impact of current bone mineral density testing rates in the medicare program.

Conference ARTHRITIS AND RHEUMATISM · September 1, 2002 Link to item Cite

Low priority of diagnostic screening of osteoporosis by primary care residents.

Conference ARTHRITIS AND RHEUMATISM · September 1, 2002 Link to item Cite

Measurement of sensation and mechanical allodynia thresholds in patients with arthropathies.

Conference ARTHRITIS AND RHEUMATISM · September 2001 Link to item Cite

Digital ulceration in scleroderma (SSc): Independent risk factors early in the disease course in three racial groups from the GENISOS cohort.

Conference ARTHRITIS AND RHEUMATISM · September 2000 Link to item Cite

Poor acculturation into mainstream America does not contribute to disease activity among Hispanic SLE patients.

Conference ARTHRITIS AND RHEUMATISM · September 1999 Link to item Cite

Predictors of self-reported function in a multi-ethnic scleroderma cohort.

Conference ARTHRITIS AND RHEUMATISM · September 1999 Link to item Cite